Longeveron rises on potential European patent related to cell therapy
25/08/2022 14:23
** Shares of biotech company Longeveron Inc LGVN.O rise
~7% to $5.57 premarket
** LGVN says European Patent Office issued notice of its
intent to grant LGVN a patent related to its lead cell therapy
candidate, Lomecel-B urn:newsml:reuters.com:*:nGNXb3sg5c
** Says after the patent grant, co will begin the process of
registering the patent in many European member nations
** Co is testing Lomecel-B for several diseases, including a
rare heart defect; the therapy is currently in a mid-stage trial
among infants with the heart defect
** The patent is expected to expire in November of 2035 -
company
** As of last close, stock down ~57% YTD
(Reporting by Raghav Mahobe)
((Raghav.Mahobe@thomsonreuters.com;))